The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 701–800 of 1,006
Identification and Characterization of Acidic Mammalian Chitinase Inhibitors
Cole, D. C., Olland, A. M., Jacob, J., Brooks, J. C. W., Bursavich, M. G., Czerwiński, R., DeClercq, C., Johnson, M. C., Joseph‐McCarthy, D., Ellingboe, J. W., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100533p · Cited by 41
Stupple, P. A., Batchelor, D. V., Corless, M., Dorr, P. K., Ellis, D. A., Fenwick, D. R., Galan, S. R. G., Jones, R. M., Mason, H. J., Middleton, D. S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100978n · Cited by 41
Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomesPreprint
Artemov, A. V., Lane, E., Vanhaelen, Q., Aliper, A. M., Ozerov, I. V., & Zhavoronkov, A. A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/095653 · Cited by 47
“This procedure contributed to improving the drug discovery process by providing a set of practical filters for many drug development pipelines (Leeson and Springthorpe 2007).”
BackgroundMethodRoehrig, S., Ackerstaff, J., Núñez, E. J., Teller, H., Ellerbrock, P., Meier, K., Heitmeier, S., Tersteegen, A., Stampfuss, J. J., Lang, D. H., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00795 · Cited by 43
Design Principles for Balancing Lipophilicity and Permeability in beyond Rule of 5 Space
Möbitz, H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300395 · Cited by 44
Exploratory analysis of kinetic solubility measurements of a small molecule library
Guha, R., Dexheimer, T. S., Kestranek, A., Jadhav, A., Chervenak, A., Ford, M. G., Simeonov, A. M., Roth, G. P., & Thomas, C. J. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.05.005 · Cited by 40
Hansen, A. H., Sergeev, E., Bolognini, D., Sprenger, R. R., Ekberg, J. H., Ejsing, C. S., McKenzie, C. J., Ulven, E. R., Milligan, G., & Ulven, T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00855 · Cited by 41
Axially Chiral Cyclic Phosphoric Acid Enabled Enantioselective Sequential Additions
Yuan, X., Wu, X., Zhang, P., Fei, P., Liu, C., Yang, H., Zhu, C., & Fu, H. (2019) · Organic Letters · doi:10.1021/acs.orglett.8b04012 · Cited by 41
Lu, Y., Vibhute, S. M., Li, L., Okumu, A. A., Ratigan, S. C., Dellos-Nolan, S., Papa, J. L., Mann, C. A., English, A., Chen, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01250 · Cited by 41
Vallianatou, T., Giaginis, C., & Tsantili‐Kakoulidou, A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-08927-0_21 · Cited by 43
Orita, M., Ohno, K., Warizaya, M., Amano, Y., & Niimi, T. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00015-7 · Cited by 47
Dow, R., Carpino, P., Gautreau, D., Hadcock, J., Iredale, P. A., Kelly-Sullivan, D. M., Lizano, J. S., O'Connor, R. E., Schneider, S. R., Scott, D., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3000325 · Cited by 33
In Vitro Measurement of Drug Efficiency Index to Aid Early Lead Optimization
Valko, K. L., Chiarparin, E., Nunhuck, S., & Montanari, D. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23305 · Cited by 40
Yeung, K. S., Qiu, Z., Yin, Z., Trehan, A. K., Fang, H., Pearce, B. C., Yang, Z., Zadjura, L. M., D’Arienzo, C. J., Riccardi, K. A., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.117 · Cited by 40
Brazidec, J. L., Pasis, A., Tam, B. Y. Y., Boykin, C., Black, C., Wang, D., Claassen, G. F., Chong, J.-H., Chao, J., Fan, J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.019 · Cited by 40
Annedi, S. C., Ramnauth, J., Maddaford, S. P., Renton, P., Rakhit, S., Mladenova, G., Dove, P., Silverman, S., Andrews, J. S., Felice, M. D., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201564u · Cited by 40
Latent Molecular Optimization for Targeted Therapeutic DesignPreprint
Aumentado‐Armstrong, T. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1809.02032 · Cited by 49
“We also looked at three chemical properties, known to be associated with drug-likeness: the partition coefficient logP, which controls the lipophilicity (and thus affects the pharmacokinetic and ADMET properties of the molecule [6, 65]), the Quantitative Estimation of Drug-Likeness (QED), which attempts to quantify th…”
BackgroundWoltering, T. J., Wichmann, J., Goetschi, E., Knoflach, F., Ballard, T. M., Huwyler, J., & Gatti, S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.125 · Cited by 39
Predictivity of Simulated ADME AutoQSAR Models over Time
Rodgers, S. L., Davis, A. M., Tomkinson, N. P., & Waterbeemd, H. V. D. (2011) · Molecular Informatics · doi:10.1002/minf.201000160 · Cited by 42
Roskoski, R. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.813015 · Cited by 40
“Leeson and Springthorpe suggest that compound lipophilicity, as estimated by cLogP, is the most important chemical property to consider during drug development [47].”
BackgroundDíaz, J. L., Christmann, U., Fernández, A., Luengo, M., Bordas, M., Enrech, R., Carro, M., Pascual, R., Burgueño, J., Merlos, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400181k · Cited by 42
Lemurell, M., Ulander, J., Winiwarter, S., Dahlén, A., Davidsson, Ö., Emtenäs, H., Broddefalk, J., Swanson, M., Hovdal, D., Plowright, A. T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501531v · Cited by 40
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV
Kim, M. B., Giesler, K. E., Tahirovic, Y. A., Truax, V. M., Liotta, D. C., & Wilson, L. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254615 · Cited by 43
“The success of MVC and the failures of VVC and AVC have recently been scrutinized in reference to lack of druglikeness in these compounds as the potential reasons for failure in the clinic and setting the stage for future innovation [62].”
BackgroundMedicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits
Sebastián-Pérez, V., Roca, C., Awale, M., Reymond, J., Martínez, A., Gil, C., & Campillo, N. E. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00401 · Cited by 39
Vadloori, B., Sharath, A. K., Prabhu, N. P., & Maurya, R. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3354-1 · Cited by 40
“Drug‐likeness prediction Drug-likeness of WA [31, 32] was calculated using molsoft server (http://molso ft.”
MethodSun, S., Jia, Q., Zenova, A., Wilson, M. S., Chowdhury, S., Focken, T., Li, J., Decker, S., Grimwood, M., Andrez, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01621 · Cited by 40
Covalent Organic Frameworks toward Diverse Photocatalytic Aerobic Oxidations
Liu, S., Tian, M., Bu, X., Tian, H., & Yang, X. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202100398 · Cited by 39
Nakagawa, S., Bainbridge, K. A., Butcher, K. J., Ellis, D. J., Klute, W., & Ryckmans, T. (2011) · ChemMedChem · doi:10.1002/cmdc.201100339 · Cited by 39
Large, J. M., Osborne, S. A., Smiljanic-Hurley, E., Ansell, K. H., Jones, H. M., Taylor, D. L., Clough, B., Green, J. L., & Holder, A. A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.010 · Cited by 40
Xiong, Y., Su, H.-F., Lv, P., Ma, Y., Wang, S., Miao, H., Liu, H., Tan, J., Ou, T., Gu, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5521 · Cited by 42
“Compounds that contain polycyclic alkaloids often exhibit improved solubility and can facilitate salt formation, which are important for oral absorption and bioavailability [43].”
Quantifying, Visualizing, and Monitoring Lead Optimization
Maynard, A. T., & Roberts, C. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00948 · Cited by 41
Dickson, C. J., Horn̆ák, V., Velez‐Vega, C., McKay, D. J., Reilly, J., Sandham, D. A., Shaw, D., Fairhurst, R. A., Charlton, S. J., Sykes, D. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00358 · Cited by 41
Silva, T., Mohamed, T., Shakeri, A., Rao, P. P. N., Martínez‐González, L., Pérez, D. I., Martı́nez, A., Valente, M. J., Garrido, J. M. P. J., Uriarte, E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00666 · Cited by 39
“With the exception of 14, the LLE was above 5, which is a value suitable for drug candidates.(46)”
BackgroundResultSmith, G. F. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04801-2 · Cited by 42
Synthesis and Biological Studies of Benzo[b]furan Derivatives: A Review from 2011 to 2022
Arce-Ramos, L., Castillo, J., & Becerra, D. (2023) · Pharmaceuticals · doi:10.3390/ph16091265 · Cited by 38
García‐Sosa, A. T., Oja, M., Hetényi, C., & Maran, U. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200587h · Cited by 39
Liu, Q., Yang, H., Jiang, Y., Zhao, Y., & Fu, H. (2013) · RSC Advances · doi:10.1039/c3ra41644e · Cited by 38
Cummings, M. D., Lin, T., Hu, L., Tahri, A., McGowan, D. C., Amssoms, K., Last, S., Devogelaere, B., Rouan, M. C., Vijgen, L., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200110 · Cited by 39
Compound high-quality criteria: a new vision to guide the development of drugs, current situation
Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.005 · Cited by 46
Liu, N., Wei, L., Huang, L., Yu, F., Zheng, W., Qin, B., Dong‐Qin, Z., Morris-Natschke, S. L., Jiang, S., Chen, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01827 · Cited by 38
Guo, J., Zhu, M., Wu, T., Hao, C., Wang, K., Yan, Z., Huang, W., Wang, J., Zhao, D., & Cheng, M. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.047 · Cited by 38
Copper-Catalyzed Chan–Lam Cyclopropylation of Phenols and Azaheterocycles
Derosa, J., O'Duill, M. L., Holcomb, M., Boulous, M. N., Patman, R. L., Wang, F., Tran‐Dubé, M., McAlpine, I., & Engle, K. M. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b03100 · Cited by 38
Zhang, M., Wang, Z., Zhang, Y., Guo, W., & Ji, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00068 · Cited by 39
The role and impact of high throughput biomimetic measurements in drug discovery
Bunally, S. B., & Young, R. J. (2018) · ADMET & DMPK · doi:10.5599/admet.530 · Cited by 40
“Such measurements can be used not only as surrogates to model and predict behaviour, but also to estimate the quality of a given molecule and thus its chances of progression [2,3]; indeed, high clinical attrition rates have been attributed to sub-optimal physicochemical properties [4,5].”
Backgroundda Silva, L. P., Núñez-Montenegro, A., Magalhães, C. M., Ferreira, P. J. O., Duarte, D., González-Berdullas, P., Rodríguez-Borges, J. E., Vale, N., & da Silva, J. C. G. E. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111683 · Cited by 38
Tafreshi, N. K., Kil, H., Pandya, D. N., Tichacek, C. J., Doligalski, M. L., Budzevich, M. M., Delva, N. C., Langsen, M., Vallas, J. A., Boulware, D. C., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00035 · Cited by 40
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Nawar, N., Bukhari, S., Adile, A., Suk, Y., Manaswiyoungkul, P., Toutah, K., Olaoye, O. O., Raouf, Y. S., Sedighi, A., Garcha, H. K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01585 · Cited by 38
Chen, H., Engkvist, O., Blomberg, N., & Li, J. (2011) · MedChemComm · doi:10.1039/c2md00238h · Cited by 40
Size does matter! Label-free detection of small molecule–protein interaction
Fechner, P., Bleher, O., Ewald, M., Freudenberger, K., Furin, D., Hilbig, U., Kolarov, F., Krieg, K., Leidner, L., Markovic, G., et al. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7834-4 · Cited by 41
“For example, some literature [3, 4] sets the limit at 1000Da, whereas 500 Da is the upper threshold for others [5, 6].”
BackgroundDiscovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist
Zheng, Y., Zhuang, L., Fan, K. Y., Tice, C. M., Zhao, W. L., Dong, C., Lotesta, S. D., Leftheris, K., Lindblom, P. R., Liu, Z., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02029 · Cited by 41
Advances in Activity Cliff Research
Dimova, D., & Bajorath, J. (2016) · Molecular Informatics · doi:10.1002/minf.201600023 · Cited by 38
Hit-to-Lead: Hit Validation and Assessment
Hevener, K. E., Pesavento, R. P., Ren, J., Lee, H., Ratia, K. M., & Johnson, M. E. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.09.022 · Cited by 48
Small Molecule Ghrelin Receptor Inverse Agonists and Antagonists
Cameron, K. O., Bhattacharya, S. K., & Loomis, A. K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003183 · Cited by 40
Increasing the delivery of next generation therapeutics from high throughput screening libraries
Wigglesworth, M. J., Murray, D. C., Blackett, C., Kossenjans, M., & Nissink, J. W. M. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.04.006 · Cited by 38
Evenäs, J., Edfeldt, F., Lepistö, M., Svitacheva, N., Synnergren, A., Lundquist, B., Gränse, M., Rönnholm, A., Varga, M., Wright, J., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.050 · Cited by 38
Southan, C., Boppana, K., Jagarlapudi, S. A. R. P., & Mureşan, S. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-14 · Cited by 37
“Their combined utility for mining drug research data has already been described [11-14].”
BackgroundMao, F., Kong, Q., Wei Min, N. I., Xu, X., Ling, D., Lu, Z., & Li, J. (2016) · ChemistryOpen · doi:10.1002/open.201600015 · Cited by 44
Reddy, D. S., Kongot, M., Singh, V., Maurya, N. S., Patel, R., Singhal, N. K., Avecilla, F., & Kumar, A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103212 · Cited by 37
Bennett-Lenane, H., O’Shea, J. P., O’Driscoll, C. M., & Griffin, B. T. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.08.008 · Cited by 39
Identification and validation of selective deubiquitinase inhibitors
Varca, A. C., Casalena, D. E., Chan, W. C., Hu, B., Magin, R. S., Roberts, R. M., Liu, X., Zhu, H., Seo, H., Dhe‐Paganon, S., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.012 · Cited by 45
Swiss ADME properties screening of the phytochemical compounds present in Bauhinia acuminata
Sravika, N., Priya, S., Divya, N., Jyotsna, P. M. S., Anusha, P., Kudumula, N., & Bai, S. A. (2021) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2021.v10.i4e.14193 · Cited by 37
“Lipophilicity is a paramount parameter in drug discovery and design (Leeson & Springthorpe, 2007) [19] because it complements the single most informational and successful physicochemical property in medicinal chemistry (Testa et al., 2000) [20].”
BackgroundThe chemist as astronaut: Searching for biologically useful space in the chemical universe
Triggle, D. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.015 · Cited by 38
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Staben, S. T., Siu, M., Goldsmith, R. A., Olivero, A. G., Do, S., Burdick, D. J., Heffron, T. P., Dotson, J., Sutherlin, D. P., Zhu, B., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.124 · Cited by 37
O’Brien-Brown, J., Jackson, A. R., Reekie, T. A., Barron, M. L., Werry, E. L., Schiavini, P., McDonnell, M., Munoz, L., Wilkinson, S. M., Noll, B. D., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.060 · Cited by 39
A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy
Pastuch-Gawołek, G., Szreder, J., Domińska, M., Pielok, M., Cichy, P., & Grymel, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030913 · Cited by 39
“For example, compounds with good oral absorption are defined by the ‘Rule of Five’ (RoF) formulated by Lipinski [273,274].”
BackgroundKaya, S., Siddique, F., Işın, D. Ö., Katin, K. P., Asati, V., & Бериша, А. (2024) · Results in Surfaces and Interfaces · doi:10.1016/j.rsurfi.2024.100184 · Cited by 36
An analysis of the physicochemical properties of oral drugs from 2000 to 2022
Pirie, R., Stanway‐Gordon, H. A., Stewart, H. L., Wilson, K. L., Patton, S., Tyerman, J., Cole, D. J., Fowler, K., & Waring, M. J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00160e · Cited by 43
Efficiency of hit generation and structural characterization in fragment-based ligand discovery
Larsson, A., Jansson, A. E., Åberg, A., & Nordlund, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.06.008 · Cited by 36
A reversed sulfonamide series of selective RORc inverse agonists
van Niel, M. B., Fauber, B. P., Cartwright, M. W., Gaines, S., Killen, J. C., René, O., Ward, S. I., Boenig, G. D. L., Deng, Y., Eidenschenk, C., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.037 · Cited by 36
Elgaher, W. A. M., Sharma, K. K., Haupenthal, J., Saladini, F., Pires, M., Réal, É., Mély, Y., & Hartmann, R. W. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00730 · Cited by 39
Deblais, L., Helmy, Y. A., Kathayat, D., Huang, H., Miller, S. A., & Rajashekara, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-31249-0 · Cited by 37
Li, Y., Zhang, F., Xu, Y., Matsumura, K., Han, Z., Liu, L.-L., Lin, W., Jia, Y., & Qian, P. (2012) · Biofouling · doi:10.1080/08927014.2012.717071 · Cited by 36
“…influence on the ADME (absorption, distribution, metabolism and excretion) properties of drugs and the environmental fate of chemicals, such as their uptake, bioaccumulation and sediment-water partition coefficients (Kubinyi et al. 1979; Cronin et al. 2006; Leeson and Springthorpe 2007).”
Funke, M., Thimm, D., Schiedel, A. C., & Müller, C. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400587g · Cited by 36
Dutta, A., Damarla, K., Kumar, A., Saikia, P. J., & Sarma, D. (2019) · Tetrahedron Letters · doi:10.1016/j.tetlet.2019.151587 · Cited by 36
Felts, A. S., Rodriguez, A. L., Smith, K. A., Engers, J. L., Morrison, R. D., Byers, F. W., Blobaum, A. L., Locuson, C. W., Chang, S., Venable, D. F., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01371 · Cited by 35
Boccard, J., Bajot, F., Pietro, A. D., Rudaz, S. L., Boumendjel, A., Nicolle, E., & Carrupt, P. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.09.009 · Cited by 35
Verheij, M. H. P., de Graaf, C., de Kloe, G. E., Nijmeijer, S., Vischer, H. F., Smits, R. A., Zuiderveld, O. P., Hulscher, S. T. M., Silvestri, L., Thompson, A. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.123 · Cited by 36
Sukerkar, P. A., MacRenaris, K. W., Townsend, T. R., Ahmed, R. A., Burdette, J. E., & Meade, T. J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2003555 · Cited by 35
Azevedo, C. M. G., Afonso, C., Soares, J. X., Reis, S., Sousa, D., Lima, R. T., Vasconcelos, M. H., Pedro, M., Barbosa, J., Gales, L., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.012 · Cited by 35
Optimization of Substrate‐Analogue Furin Inhibitors
Ivanova, T., Hardes, K., Kallis, S., Dahms, S. O., Than, M. E., Künzel, S., Böttcher‐Friebertshäuser, E., Lindberg, I., Jiao, G., Bartenschlager, R. F. W., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700596 · Cited by 35
Nakahata, T., Tokumaru, K., Ito, Y., Ishii, N., Setoh, M., Shimizu, Y., Harasawa, T., Aoyama, K., Hamada, T., Kori, M., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.005 · Cited by 35
Shiri, F., Pirhadi, S., & Ghasemi, J. B. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1468281 · Cited by 35
“Ligand efficiency indices give an indication of the free binding energy per heavy atom and can better identify potential drug candidates (Leeson & Springthorpe, 2007).”
BackgroundXiong, Y., Greschik, H., Johansson, C., Seifert, L., Bacher, J., Park, K., Babault, N., Martini, M. L., Fagan, V., Li, F., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00522 · Cited by 35
Nowak, M., Dyba, A. J., Janczak, J., Morritt, A. L., Fábián, L., Karolewicz, B., Khimyak, Y. Z., Braun, D. E., & Nartowski, K. P. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00752 · Cited by 35
Computational Analysis of Structure–Activity Relationships
Gedeck, P., Krämer, C., & Ertl, P. (2010) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(10)49004-9 · Cited by 46
Hermone, A. R., Burnett, J. C., Nuss, J. E., Tressler, L. E., Nguyen, T. L., Šolaja, B. A., Vennerstrom, J. L., Schmidt, J. J., Wipf, P., Bavari, S., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800241 · Cited by 35
Hutchings, C. J., Cseke, G., Osborne, G. J., Woolard, J., Zhukov, A., Koglin, M., Jazayeri, A., Pandya-Pathak, J., Langmead, C. J., Hill, S. J., et al. (2013) · mAbs · doi:10.4161/mabs.27226 · Cited by 39
“Many small-molecule compounds derived from high throughput screening approaches have high lipophilicity and molecular weight leading to an increased probability of off-target toxicity.(2) An alternative approach to GPCR drug discovery is to identify functional antibodies that selectively activate or inhibit GPCRs of i…”
BackgroundFinding the rules for successful drug optimisation
Yusof, I., Shah, F., Hashimoto, T., Segall, M., & Greene, N. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.005 · Cited by 35
Steuer, C., Huber, A. R., & Bernasconi, L. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.08.014 · Cited by 35
Ramesh, R., Nagasundaram, N., Meignanasundar, D., Vadivel, P., & Lalitha, A. (2016) · Research on Chemical Intermediates · doi:10.1007/s11164-016-2728-z · Cited by 35
Kaur, J. P., Soto‐Velasquez, M., Ding, Z. J., Ghanbarpour, A., Lill, M. A., van Rijn, R. M., Watts, V. J., & Flaherty, D. P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.036 · Cited by 36
Accelerated drug discovery by rapid candidate drug identification
Bergström, F., & Lindmark, B. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.026 · Cited by 37
Property-Based Drug Design Merits a Nobel Prize
Pennington, L. D., Hesse, M. J., Koester, D. C., McAtee, R. C., Qunies, A. M., & Hu, D. X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01345 · Cited by 37
The changing landscape of medicinal chemistry optimization
Rácz, A., Mihalovits, L. M., Beckers, M., Fechner, N., Stiefl, N., Sirockin, F., McCoull, W., Evertsson, E., Lemurell, M., Makara, G. M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01225-1 · Cited by 52
“13 and 14) revealed similar trends to those discussed above.”
InfluentialA New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
Jiménez-Dı́az, M. B., Viera, S., Ibáñez, J., Mulet, T., Magán-Marchal, N., Garuti, H., Gómez, V., Cortés-Gil, L., Martínez, A., Ferrer, S. B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066967 · Cited by 34
“efficacious compounds and the quality of leads [60,61].”
BackgroundPhysicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds
Tyrchan, C., Blomberg, N., Engkvist, O., Kogej, T., & Mureşan, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.068 · Cited by 34
Translational paradigms in pharmacology and drug discovery
Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.019 · Cited by 35
Collation and data-mining of literature bioactivity data for drug discovery
Bellis, L. J., Akhtar, R. A., Al‐Lazikani, B., Atkinson, F. L., Bento, A. P., Chambers, J. K., Davies, M., Gaulton, A., Hersey, A., Ikeda, K., et al. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391365 · Cited by 35
Computational Macrocyclization: From de novo Macrocycle Generation to Binding Affinity Estimation
Wagner, V., Jantz, L., Briem, H., Sommer, K., Rarey, M., & Christ, C. D. (2017) · ChemMedChem · doi:10.1002/cmdc.201700478 · Cited by 34
Challenges with multi-objective QSAR in drug discovery
Lambrinidis, G., & Tsantili‐Kakoulidou, A. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1496079 · Cited by 37
“The concept of drug-likeness has been launched to define boundaries on the chemical space and to function as filter to guarantee a physicochemical profile enabling further development [22,23].”
Background
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.